Vivani Medical Inc
VANI1.330USD
0.000
Market hours （ET）Quotes delayed by 15 min
78.79MMarket Cap
LossP/E TTM
More Details of Vivani Medical Inc Company
Vivani Medical, Inc. is a biopharmaceutical company developing novel, ultra-long-acting drug implants. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.
Company Info
Ticker SymbolVANI
Company nameVivani Medical Inc
IPO dateDec 05, 2014
CEODr. Adam Mendelsohn, Ph.D.
Number of employees42
Security typeOrdinary Share
Fiscal year-endDec 05
Address1350 S. Loop Road
CityALAMEDA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94502
Phone14155068462
Websitehttps://vivani.com/
Ticker SymbolVANI
IPO dateDec 05, 2014
CEODr. Adam Mendelsohn, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Adam Mendelsohn, Ph.D.
Dr. Adam Mendelsohn, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
3.75M
+1.58%
Mr. Aaron Mendelsohn
Mr. Aaron Mendelsohn
Independent Director
Independent Director
1.09M
--
Mr. Truc Le
Mr. Truc Le
Chief Operating Officer
Chief Operating Officer
46.66K
--
Mr. Donald (Don) Dwyer
Mr. Donald (Don) Dwyer
Corporate Secretary, Chief Business Officer
Corporate Secretary, Chief Business Officer
25.67K
+18.46%
Mr. Anthony Baldor
Mr. Anthony Baldor
Chief Financial Officer
Chief Financial Officer
--
--
Jami Taylor
Jami Taylor
Investor Relations Advisor
Investor Relations Advisor
--
--
Dr. Dean Baker, Ph.D.
Dr. Dean Baker, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregg G. Williams
Mr. Gregg G. Williams
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Independent Director
Independent Director
--
--
Ms. Alexandra Larson
Ms. Alexandra Larson
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Adam Mendelsohn, Ph.D.
Dr. Adam Mendelsohn, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
3.75M
+1.58%
Mr. Aaron Mendelsohn
Mr. Aaron Mendelsohn
Independent Director
Independent Director
1.09M
--
Mr. Truc Le
Mr. Truc Le
Chief Operating Officer
Chief Operating Officer
46.66K
--
Mr. Donald (Don) Dwyer
Mr. Donald (Don) Dwyer
Corporate Secretary, Chief Business Officer
Corporate Secretary, Chief Business Officer
25.67K
+18.46%
Mr. Anthony Baldor
Mr. Anthony Baldor
Chief Financial Officer
Chief Financial Officer
--
--
Jami Taylor
Jami Taylor
Investor Relations Advisor
Investor Relations Advisor
--
--
Revenue Breakdown
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
2.20M
0.00%
Italy
642.04K
0.00%
China
337.90K
0.00%
France
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Williams (Gregg)
30.87%
Bolck (Joachim Eberhard)
9.45%
Mendelsohn (Adam)
6.34%
Mendelsohn (Aaron)
1.83%
Tanager Wealth Management LLP
1.72%
Other
49.79%
Shareholders
Shareholders
Proportion
Williams (Gregg)
30.87%
Bolck (Joachim Eberhard)
9.45%
Mendelsohn (Adam)
6.34%
Mendelsohn (Aaron)
1.83%
Tanager Wealth Management LLP
1.72%
Other
49.79%
Shareholder Types
Shareholders
Proportion
Individual Investor
49.03%
Investment Advisor
4.84%
Investment Advisor/Hedge Fund
2.56%
Hedge Fund
0.28%
Other
43.29%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
69
33.60M
56.72%
-556.17K
2025Q1
72
33.70M
56.88%
-726.81K
2024Q4
67
33.96M
57.33%
+2.68M
2024Q3
70
30.79M
54.55%
-493.25K
2024Q2
72
30.73M
54.46%
-999.37K
2024Q1
71
31.19M
60.37%
+7.51M
2023Q4
76
28.47M
55.90%
+4.85M
2023Q3
88
28.13M
55.24%
+3.68M
2023Q2
94
27.99M
55.13%
+4.81M
2023Q1
98
20.48M
40.40%
+6.26M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Williams (Gregg)
18.29M
30.87%
+105.15K
+0.58%
Apr 22, 2025
Bolck (Joachim Eberhard)
5.60M
9.45%
--
--
Mar 31, 2025
Mendelsohn (Adam)
3.75M
6.34%
+58.33K
+1.58%
Mar 31, 2025
Mendelsohn (Aaron)
1.09M
1.83%
--
--
Mar 31, 2025
Tanager Wealth Management LLP
1.22M
2.07%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
967.40K
1.63%
--
--
Mar 31, 2025
Sabby Management, LLC
851.61K
1.44%
-459.83K
-35.06%
Mar 31, 2025
Geode Capital Management, L.L.C.
360.53K
0.61%
+13.37K
+3.85%
Mar 31, 2025
Commonwealth Financial Network
330.53K
0.56%
--
--
Mar 31, 2025
Baker (Wilford Dean)
197.48K
0.33%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Date
Type
Ratio
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
